Project Grant HT94252410938
Award Date
12/1/24
Completion Date
11/30/26
Dollars Obligated
$346K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Great Britain, United Kingdom
Similar Awards
This $563,484.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by Duke University to regulate skeletal muscle fibrosis in Duchenne muscular dystrophy. The two-year award, effective June 1, 2024 through May 31, 2026, will enable Duke University's research team to advance understanding and potential treatments for this debilitating neuromuscular disorder affecting military service members and...
The federal Project Grant award of $1,008,313.00 was provided by the Defense Health Agency through the Military Medical Research and Development program (CFDA 12.420) to The Regents of the University of California, San Francisco (UCSF). The grant, awarded on September 1, 2024, supports advanced biomedical research initiatives focused on transforming healthcare for military service members and the broader public. The award will fund innovative scientific investigations spanning basic, applied,...
This $1,464,751 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research conducted by the University of California, Los Angeles (UCLA) to develop adeno-associated virus (AAV) vectors targeted to muscle and muscle stem cells. The goal is to improve the therapeutic efficacy and safety of treatments for Duchenne muscular dystrophy. The award period runs from September 1, 2024 to August 31, 2027. As the prime awardee, UCLA...
The federal Project Grant award of $254,153.00 was made on March 1, 2025 by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award supports advanced biomedical research focused on the relationship between microplastics and prostate cancer at New York University School of Medicine, a prominent academic medical center and research institution. The funding will enable researchers to investigate innovative approaches to disease prevention,...
This $661,501 federal Project Grant award was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of California, Los Angeles (UCLA) for the period of September 1, 2024 through August 31, 2027. The award will fund research to develop AAV (adeno-associated virus) vectors targeted to muscle and muscle stem cells, which offer improved therapeutic efficacy and safety for treating Duchenne muscular dystrophy. UCLA, through...
The federal Project Grant award of $1,214,375.00 from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), is funding a research project led by Yale University. The project is investigating the use of decoy-resistant IL-18 and immune checkpoint inhibitors in preclinical murine and ex vivo patient-derived models of renal cell carcinoma. The award began on September 15, 2024 and is set to conclude on September 14, 2028. The Military Medical Research...
The federal Project Grant award of $320,000.00, issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research by The General Hospital Corporation (Massachusetts General Hospital) to investigate gamma delta T cell ligands in multiple sclerosis. The award, with a performance period from November 1, 2024 to October 31, 2026, will fund advanced biomedical research initiatives focused on transforming healthcare for military service...
The federal Project Grant award, valued at $188,000.00, was provided by the Defense Health Agency to The Institute For Cancer Research, a non-profit research organization located in Cheltenham, Pennsylvania. The grant, under the Military Medical Research and Development program (CFDA 12.420), will support research focused on repairing NF2 mutations using prime editing techniques. The research aims to advance the understanding and treatment of genetic disorders, with a focus on applications...
<p>The Defense Health Agency awarded Wake Forest University Health Sciences a $542,500 Project Grant under the Military Medical Research and Development (CFDA 12.420) program. The grant will fund high-throughput screening to identify lipid nanoparticles effective for systemic delivery to tissues affected by Duchenne muscular dystrophy. The research is scheduled to be completed by September 29, 2025.</p>
The federal Project Grant award of $659,922, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports a gene therapy research project for nuclear TDP-43 supplementation at Macquarie University in Australia. The research aims to develop a pathway for delaying the onset of neurodegenerative diseases. The award, effective from September 15, 2025 to September 14, 2027, will fund sophisticated research and development activities...